Last updated: April 18, 2025
Sponsor: Ain Shams University
Overall Status: Active - Recruiting
Phase
3
Condition
Obesity
Treatment
lactobacillus LS
Clinical Study ID
NCT06936137
MD343/2024
Ages 18-45 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Adult schizophrenia patients (18-45 years) on second generation antipsychoticsStable patients with a total positive and negative syndrome scale (PANSS) score of ≤60.
With more than 10% weight gain after taking atypical antipsychotics for at least 3 months with treatment duration not more than two years.
Exclusion
Exclusion Criteria:
Taking probiotics, fiber supplements, antibiotics and laxatives in the last 6 weeks.
Comorbid gastrointestinal diseases, including active peptic ulcer, uncontrolled andrecurrent diarrhea, gastrointestinal bleeding, and digestive system neoplasticdiseases.
Study Design
Total Participants: 180
Treatment Group(s): 1
Primary Treatment: lactobacillus LS
Phase: 3
Study Start date:
April 20, 2025
Estimated Completion Date:
December 20, 2026
Connect with a study center
AinShams university hospitals
Cairo, Abbassia 00202
EgyptActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.